TRPM8 as an Anti-Tumoral Target in Prostate Cancer Growth and Metastasis Dissemination.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Jun 2022
Historique:
received: 07 05 2022
revised: 05 06 2022
accepted: 12 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

In the fight against prostate cancer (PCa), TRPM8 is one of the most promising clinical targets. Indeed, several studies have highlighted that TRPM8 involvement is key in PCa progression because of its impact on cell proliferation, viability, and migration. However, data from the literature are somewhat contradictory regarding the precise role of TRPM8 in prostatic carcinogenesis and are mostly based on in vitro studies. The purpose of this study was to clarify the role played by TRPM8 in PCa progression. We used a prostate orthotopic xenograft mouse model to show that TRPM8 overexpression dramatically limited tumor growth and metastasis dissemination in vivo. Mechanistically, our in vitro data revealed that TRPM8 inhibited tumor growth by affecting the cell proliferation and clonogenic properties of PCa cells. Moreover, TRPM8 impacted metastatic dissemination mainly by impairing cytoskeleton dynamics and focal adhesion formation through the inhibition of the Cdc42, Rac1, ERK, and FAK pathways. Lastly, we proved the in vivo efficiency of a new tool based on lipid nanocapsules containing WS12 in limiting the TRPM8-positive cells' dissemination at metastatic sites. Our work strongly supports the protective role of TRPM8 on PCa progression, providing new insights into the potential application of TRPM8 as a therapeutic target in PCa treatment.

Identifiants

pubmed: 35743115
pii: ijms23126672
doi: 10.3390/ijms23126672
pmc: PMC9224463
pii:
doi:

Substances chimiques

Membrane Proteins 0
TRPM Cation Channels 0
TRPM8 channel-associated factor 1 protein, human 0
TRPM8 protein, human 0
TRPM8 protein, mouse 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Institut Universitaire de France
ID : Gkika 2017
Organisme : French National Cancer Institute
ID : INCa- PLBIO14-213
Organisme : PRIN grant
ID : 20174TB8KW

Références

Tumour Biol. 2014 Feb;35(2):1251-61
pubmed: 24037916
Asian J Androl. 2009 Mar;11(2):157-65
pubmed: 19234481
Cell Death Dis. 2019 Sep 9;10(9):652
pubmed: 31501416
Pathol Oncol Res. 2012 Oct;18(4):903-10
pubmed: 22437241
Front Physiol. 2013 Nov 05;4:311
pubmed: 24204345
Pharmaceuticals (Basel). 2016 Jul 09;9(3):
pubmed: 27409624
Sci Rep. 2017 Dec 22;7(1):18071
pubmed: 29273771
Biochim Biophys Acta. 2007 Aug;1772(8):937-46
pubmed: 17616360
Int J Biol Sci. 2013 Dec 22;10(1):90-102
pubmed: 24391455
Physiol Rev. 2018 Apr 1;98(2):559-621
pubmed: 29412049
Endocr Relat Cancer. 2005 Jun;12(2):367-82
pubmed: 15947109
J Biol Chem. 2012 Jan 27;287(5):2948-62
pubmed: 22128173
J Cell Biol. 1997 Nov 17;139(4):1047-59
pubmed: 9362522
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Invest. 2007 Jun;117(6):1647-57
pubmed: 17510704
Mol Cancer. 2014 Dec 11;13:264
pubmed: 25496128
Nat Rev Cancer. 2007 Jul;7(7):519-30
pubmed: 17585332
J Cell Biol. 2015 Jan 5;208(1):89-107
pubmed: 25559186
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Cancer Res. 2001 May 1;61(9):3760-9
pubmed: 11325849
Cancer Res. 2003 Jul 15;63(14):4196-203
pubmed: 12874026
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
Biochim Biophys Acta. 2009 Jun;1793(6):1105-9
pubmed: 19339216
Biomaterials. 2014 Oct;35(30):8635-48
pubmed: 25028336
J Biol Chem. 2000 Apr 14;275(15):11470-7
pubmed: 10753965
Sci Rep. 2019 May 28;9(1):7926
pubmed: 31138874
J Cell Biol. 2000 Aug 7;150(3):567-80
pubmed: 10931868
Oncol Lett. 2016 Jan;11(1):182-188
pubmed: 26870186
Nat Rev Cancer. 2008 May;8(5):361-75
pubmed: 18432251
Carcinogenesis. 2014 Dec;35(12):2787-97
pubmed: 25269802
Oncol Lett. 2011 Nov;2(6):1213-1217
pubmed: 22848290
Oncogene. 2010 Aug 12;29(32):4611-6
pubmed: 20531306
Prostate. 2006 Oct 1;66(14):1521-34
pubmed: 16921506
Oncol Lett. 2015 Sep;10(3):1378-1384
pubmed: 26622677
Int J Oncol. 2010 Feb;36(2):443-50
pubmed: 20043080
Br J Cancer. 2014 Jan 21;110(2):469-78
pubmed: 24346288
Eur Respir Rev. 2017 Jan 31;26(143):
pubmed: 28143875
Mol Biol Cell. 1999 Jan;10(1):9-22
pubmed: 9880323
Mol Biol Cell. 2001 Aug;12(8):2257-74
pubmed: 11514615
J Cell Biol. 2017 Jul 3;216(7):2107-2130
pubmed: 28550110
Pflugers Arch. 2011 Jan;461(1):99-114
pubmed: 21052713
Cancer Res. 2006 Feb 15;66(4):2038-47
pubmed: 16489003
J Biol Chem. 2005 Nov 25;280(47):39423-35
pubmed: 16174775
Int J Pharm. 2009 Sep 11;379(2):201-9
pubmed: 19409468
FASEB J. 2020 Jun;34(6):7483-7499
pubmed: 32277850
Cancer Res. 2004 Nov 15;64(22):8365-73
pubmed: 15548706
Br J Pharmacol. 2013 Jan;168(1):79-102
pubmed: 22594963
PLoS One. 2012;7(12):e51825
pubmed: 23251635

Auteurs

Guillaume P Grolez (GP)

Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d'Ascq, France.

Giorgia Chinigò (G)

Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d'Ascq, France.
Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy.

Alexandre Barras (A)

CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520-IEMN, 59000 Lille, France.

Mehdi Hammadi (M)

CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520-IEMN, 59000 Lille, France.

Lucile Noyer (L)

Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d'Ascq, France.

Kateryna Kondratska (K)

Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d'Ascq, France.

Etmar Bulk (E)

Institute of Physiology II, University of Münster, 48149 Münster, Germany.

Thibauld Oullier (T)

Cancéropôle du Grand Ouest, Plateforme In Vivo, 44000 Nantes, France.

Séverine Marionneau-Lambot (S)

Cancéropôle du Grand Ouest, Plateforme In Vivo, 44000 Nantes, France.

Marilyne Le Mée (M)

CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France.

Stéphanie Rétif (S)

CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France.

Stéphanie Lerondel (S)

CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France.

Antonino Bongiovanni (A)

CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UMS 2014-PLBS, University of Lille, 59000 Lille, France.

Tullio Genova (T)

Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy.
Nanostructured Interfaces and Surfaces Centre of Excellence (NIS), University of Turin, 10123 Turin, Italy.

Sébastien Roger (S)

Transplantation, Immunologie et Inflammation T2I-EA 4245, Université de Tours, 37044 Tours, France.

Rabah Boukherroub (R)

CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520-IEMN, 59000 Lille, France.

Albrecht Schwab (A)

Institute of Physiology II, University of Münster, 48149 Münster, Germany.

Alessandra Fiorio Pla (A)

Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d'Ascq, France.
Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy.
CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France.

Dimitra Gkika (D)

CNRS, INSERM, CHU Lille, Centre Oscar Lambret, UMR 9020-UMR 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, 59000 Villeneuve d'Ascq, France.
Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
Institut Universitaire de France (IUF), 75231 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH